- Conditions
- Plantar Fascitis
- Interventions
- Photobiomodulation Therapy (PBMT), Sham-Photobiomodualtion Therapy (Sham-PBMT)
- Device
- Lead sponsor
- The Geneva Foundation
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 263
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Seriously Ill Hospitalized Patients
- Interventions
- Default Order, Accountable Justification, Standardized Usual Care
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78,302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Pasadena, California • Livonia, Michigan
- Conditions
- Hyperphosphatemia, Anemia, Iron Deficiency, Renal Insufficiency
- Interventions
- Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy
- Drug
- Lead sponsor
- USRC Kidney Research
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Anchorage, Alaska • Mesa, Arizona • Pine Bluff, Arkansas + 6 more
- Conditions
- Alcohol Dependence, Alcohol Use Disorder
- Interventions
- XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 208
- States / cities
- Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more
- Conditions
- Prostatectomy, Opioid-Related Disorders
- Interventions
- Pre-operative Opioid Education
- Behavioral
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recreational Drug Use
- Interventions
- PF614, Oxycodone, Placebo
- Drug · Other
- Lead sponsor
- Ensysce Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Seriously Ill Hospitalized Patients
- Interventions
- Default Order, Accountable Justification, Standardized Usual Care
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Pasadena, California • Livonia, Michigan
- Conditions
- Breast Cancer, Lymphoma, Chemotherapy Effect
- Interventions
- Arterial blood pressure, Vascular Ultrasound, Venous blood sample, Skin microcirculatory blood flow
- Other
- Lead sponsor
- Carl Ade, M.S., Ph.D.
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Manhattan, Kansas
- Conditions
- D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
- Interventions
- [18F]FTP PET/CT
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV/AIDS, Stimulant Use Disorders
- Interventions
- Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS), Contingency Management (CM)
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Motor Disorders, Healthy, Spinal Cord Injuries, Muscular Diseases, Motor Neuron Disease, Stroke, Traumatic Brain Injury, Movement Disorders, Multiple Sclerosis
- Interventions
- NMES Feedback, Visual Feedback, TESS
- Device
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency
- Interventions
- GLP-1, GIP
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recreational Drug Use
- Interventions
- PF614, Oxycodone Hydrochloride 40 mg, Placebo
- Drug
- Lead sponsor
- Ensysce Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Congestive Heart Failure, Hypotension
- Interventions
- True Acupuncture, Sham Acupuncture
- Procedure
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- La Jolla, California
- Conditions
- Abuse Potential
- Interventions
- gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo
- Drug
- Lead sponsor
- Viatris Specialty LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass
- Interventions
- Nitric Oxide Gas, Standard Care Arm
- Drug
- Lead sponsor
- Xijing Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thalassemia, Sickle Cell Disease, Healthy Controls
- Interventions
- Hydroxyurea, Acetazolamide
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy
- Interventions
- ALKS 5461, Buprenorphine, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Unhealthy Alcohol Use
- Interventions
- Contingency Management Counseling, Addiction Physician Management, Motivational Enhancement Therapy
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
- Conditions
- Obesity, Cancer
- Interventions
- NOURISH-T, Enhanced Usual Care
- Behavioral
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 5 Years to 13 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- St. Petersburg, Florida • Pittsburgh, Pennsylvania
- Conditions
- Impaired Glucose Tolerance
- Interventions
- 0 mg placebo, 300 mg GSE, 600 mg GSE, 900 mg GSE
- Dietary Supplement
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
- Industry
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy
- Interventions
- Placebo, Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg, Gabapentin 600 mg + Oxycodone 20 mg, Gabapentin 1200 mg + Oxycodone 20 mg
- Drug
- Lead sponsor
- Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,725 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 219
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more